Patents by Inventor Irving L. Weissman

Irving L. Weissman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies
    Patent number: 10081680
    Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell. Antibodies that are bispecific for SIRP? and a second antigen are termed Bi-specific Macrophage Enhancing (BiME) antibodies and have emergent properties. The subject anti-SIRP? antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRP? antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRP? antibodies.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: September 25, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kipp Andrew Weiskopf, Aaron Michael Ring, Jens-Peter Volkmer, Irving L. Weissman, Nan Guo Ring
  • TREATMENT OF PEDIATRIC BRAIN TUMORS WITH TARGETING OF CD47 PATHWAY
    Publication number: 20180258170
    Abstract: Methods are provided for targeting pediatric brain tumor cells for depletion.
    Type: Application
    Filed: March 5, 2018
    Publication date: September 13, 2018
    Inventors: Sharareh Gholamin, Samuel Cheshier, Siddhartha S. Mitra, Irving L. Weissman
  • Selective immunodepletion of endogenous stem cell niche for engraftment
    Patent number: 10072091
    Abstract: The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment and tolerance.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: September 11, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, Agnieszka Czechowicz, Deepta Bhattacharya, Daniel Kraft
  • COMPOSITIONS AND METHODS FOR INDUCING PHAGOCYTOSIS OF MHC CLASS I POSITIVE CELLS AND COUNTERING ANTI-CD47/SIRPA RESISTANCE
    Publication number: 20180251558
    Abstract: Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.
    Type: Application
    Filed: October 23, 2015
    Publication date: September 6, 2018
    Inventors: Roy Louis Maute, Kipp Andrew Weiskopf, Aaron Michael Ring, Irving L. Weissman
  • Use of anti-CD47 agents to enhance immunization
    Patent number: 10064925
    Abstract: Methods are provided for enhancing immunization strategies by manipulation, e.g. in vitro manipulation, of phagocytic antigen presenting cells. In the methods of the invention, phagocytic antigen presenting cells (phAPC) are incubated with a particulate antigen in the presence of an anti-CD47 agent in a dose and for a period of time sufficient to allow the phAPC to phagocytose the particulate antigen, which process generates a “loaded” phAPC. The loaded phAPC is contacted with a population of T cells matched for at least one major histocompatibility locus with the phAPC, where the T cells are stimulated after contacting to generate an effector response against an epitope or epitopes present on the particulate antigen.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: September 4, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Diane Tseng, Jens-Peter Volkmer, Kipp Andrew Weiskopf, Stephen Willingham, Irving L. Weissman
  • NON-GENOTOXIC CONDITIONING REGIMEN FOR STEM CELL TRANSPLANTATION
    Publication number: 20180214524
    Abstract: The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection.
    Type: Application
    Filed: January 30, 2018
    Publication date: August 2, 2018
    Inventors: Irving L. Weissman, Judith A. Shizuru, Akanksha Chhabra, Benson M. George
  • HIGH AFFINITY SIRP-ALPHA REAGENTS AND METHODS OF USING
    Publication number: 20180195054
    Abstract: High affinity SIRP-? reagent are provided, which (i) comprise at least one amino acid change relative to the wild-type protein; and (ii) have an increased affinity for CD47 relative to the wild-type protein. Compositions and methods are provided for modulating phagocytosis in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity SIRP? reagent, which blocks the physiological binding interaction between SIRP? and its ligand CD47.
    Type: Application
    Filed: March 5, 2018
    Publication date: July 12, 2018
    Inventors: Aaron Michael Ring, Kenan Christopher Garcia, Kipp Andrew Weiskopf, Aron M. Levin, Irving L. Weissman
  • SIRP-ALPHA AGONIST ANTIBODY
    Publication number: 20180171030
    Abstract: Compositions and methods are provided relating to anti-SIRP? agonist antibodies. The antibodies of the invention bind to human SIRP?, and activate signaling, thereby inhibiting processes mediated by SIRP?, including without limitation phagocytosis. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRP? agonist antibodies; and cell lines that produce these antibodies.
    Type: Application
    Filed: June 8, 2016
    Publication date: June 21, 2018
    Inventors: Irving L. Weissman, Benson George, Nan Guo Ring, Aaron Michael Ring, Jens-Peter Volkmer
  • BTN3A ECTODOMAIN PROTEINS AND METHODS OF USE
    Publication number: 20180147257
    Abstract: BTN3A ectodomain polypeptides are provided, which comprise a BTN3A ectodomain (e.g., a BTN3A1, BTN3A2, or BTN3A3 ectodomain) and lack a BTN3A transmembrane domain (e.g., a BTN3A1, BTN3A2, or BTN3A3 transmembrane domain). Compositions and methods are provided for activating an antigen presenting cell (APC). In some cases, the APC is activated in vivo. For example, in some cases, APC activity is stimulated (an APC is activated) in a mammal by administering a pharmaceutical composition comprising a BTN3A ectodomain polypeptide.
    Type: Application
    Filed: May 20, 2016
    Publication date: May 31, 2018
    Inventors: Daniel Mark Corey, Aaron Michael Ring, Irving L. Weissman
  • HIGH AFFINITY CD47 ANALOGS
    Publication number: 20180127480
    Abstract: High affinity CD47 reagents are provided, which (i) comprise at least one amino acid change relative to the wild-type protein; and (ii) have an increased affinity for a SIRP? relative to the wild-type protein. Compositions and methods are provided for modulating phagocytosis in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity CD47 reagent, which blocks the physiological binding interaction between SIRP? and a ligand, e.g., native CD47.
    Type: Application
    Filed: May 5, 2016
    Publication date: May 10, 2018
    Inventors: Chia Chi Ho, Kenan Christopher Garcia, Aaron Michael Ring, Kipp Andrew Weiskopf, Irving L. Weissman, Nan Guo Ring
  • Methods for determining responsiveness to an anti-CD47 agent
    Patent number: 9957576
    Abstract: Methods and kits are provided for determining whether an individual is responsive to an anti-CD47 agent by assaying biological samples for the level or ratio of isoforms of CD47 in the sample.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: May 1, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, Victor Albert Eng, Rahul Sinha
  • High affinity Sirp-alpha reagents and methods of using
    Patent number: 9944911
    Abstract: High affinity SIRP-? reagent are provided, which (i) comprise at least one amino acid change relative to the wild-type protein; and (ii) have an increased affinity for CD47 relative to the wild-type protein. Compositions and methods are provided for modulating phagocytosis in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity SIRP? reagent, which blocks the physiological binding interaction between SIRP? and its ligand CD47.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: April 17, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Aaron Michael Ring, Kenan Christopher Garcia, Kipp Andrew Weiskopf, Aron M. Levin, Irving L. Weissman
  • Methods for determining responsiveness to an anti-CD47 agent
    Patent number: 9945870
    Abstract: Methods and kits are provided for determining whether an individual is responsive to an anti-CD47 agent and for determining whether an individual is maintaining responsiveness to an anti-CD47 agent by assaying biological samples for the level of at least one biomarker in a biological sample.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: April 17, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kipp Andrew Weiskopf, Irving L. Weissman
  • Disrupting FC Receptor Engagement on Macrophages Enhances Efficacy of Anti-SIRPalpha Antibody Therapy
    Publication number: 20180037652
    Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell. The subject anti-SIRP? antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRP? antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRP? antibodies.
    Type: Application
    Filed: July 26, 2017
    Publication date: February 8, 2018
    Inventors: Jie Liu, Aaron Michael Ring, Jens-Peter Volkmer, Irving L. Weissman
  • PRODUCING MESODERMAL CELL TYPES AND METHODS OF USING THE SAME
    Publication number: 20180030410
    Abstract: Methods are provided for the generation of mesodermal cell types and derivatives thereof. Also provided are methods for generating purified populations of mesodermal cell types and derivatives thereof. The instant disclosure also provides methods of screening for cellular responses of the generated mesodermal cell types and derivatives thereof. Also provide are methods for screening for organismal phenotypes induced by introduction of the generated mesodermal cell types and derivatives thereof. Treatment methods making use of the generated mesodermal cell types and derivatives thereof are also provided. The instant disclosure also provides systems, compositions, and kits for practicing the methods of the disclosure.
    Type: Application
    Filed: March 2, 2016
    Publication date: February 1, 2018
    Inventors: Kyle Ming Loh, Irving L. Weissman, Lay Teng Ang, Angela Chen
  • COMBINATION THERAPY FOR TREATMENT OF CORONARY ARTERY DISEASE
    Publication number: 20180028651
    Abstract: An effective combined dose of an anti-CD47 agent and an anti-TNF agent is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce atherosclerotic plaque in the individual.
    Type: Application
    Filed: February 25, 2016
    Publication date: February 1, 2018
    Inventors: Nicholas J. Leeper, Irving L. Weissman
  • MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS
    Publication number: 20180022806
    Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
    Type: Application
    Filed: September 14, 2017
    Publication date: January 25, 2018
    Inventors: Ravindra Majeti, Irving L. Weissman
  • MACROPHAGES EAT CANCER CELLS USING THEIR OWN CALRETICULIN AS A GUIDE
    Publication number: 20180000865
    Abstract: Therapeutic and diagnostic methods are provided, which methods relate to the induction of expression of calreticulin on phagocytic cells. Specifically, the methods relate to macrophage-mediated programmed cell removal (PrCR), the methods comprising increasing PrCR by contacting a phagocytic cell with a toll-like receptor (TLR) agonist; or down-regulating PrCR by contacting a phagocytic cell with an inhibitor of Bruton's tyrosine kinase (BTK). In some embodiments, an activator of TLR signaling or a BTK agonist is provided in combination with CD47 blockade.
    Type: Application
    Filed: January 21, 2016
    Publication date: January 4, 2018
    Inventors: Irving L. WEISSMAN, Mingye FENG, Jens-Peter VOLKMER
  • FACTORS AND CELLS THAT PROVIDE FOR INDUCTION OF BONE, BONE MARROW, AND CARTILAGE
    Publication number: 20170360838
    Abstract: Methods, compositions and kits for producing functional chondrocytes, skeletal cells, bone marrow stromal cells, and progenitor cells thereof are provided. These methods, compositions and kits find use in producing chondrocytes, osteoblasts, stromal cells, and progenitor cells thereof in vivo, or in vitro for transplantation, for experimental evaluation, as a source of lineage- and cell-specific products, and the like, for example for use in treating human disorders of the cartilage, bone and hematopoietic system. In some embodiments, specific combinations of protein factors are identified for reprogramming non-skeletal cells into bones, hematopoietic stroma, and chondrocytes, which may be provided in vitro or in vivo.
    Type: Application
    Filed: January 6, 2016
    Publication date: December 21, 2017
    Inventors: Charles K.F. Chan, Irving L. Weissman, Michael T. Longaker
  • CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE
    Publication number: 20170362332
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Application
    Filed: August 14, 2017
    Publication date: December 21, 2017
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman